Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.fiercebiotech.com/biotech/minoryx-clutching-data-failed-trial-knocked-back-ema-vows-seek-rerun-review
https://www.clinicaltrialsarena.com/news/fda-minoryx-phase-iii-trial-cald-therapy/
https://www.europeanpharmaceuticalreview.com/news/176282/minoryx-and-neuraxpharm-therapy-for-rare-cns-disorders/
https://www.pharmiweb.com/press-release/2022-09-20/minoryx-s-marketing-authorization-application-for-its-lead-candidate-leriglitazone-validated-by-ema-for-orphan-indication-x-linked-adrenoleukodystrophy-x-ald
https://www.fiercebiotech.com/biotech/bouncing-back-late-phase-fail-minoryx-pockets-eu51m-guide-rare-disease-drug-market
https://www.pharmiweb.com/press-release/2021-01-26/minoryx-presents-topline-results-from-phase-23-advance-study-demonstrating-significant-clinical-benefit-of-leriglitazone-in-adrenomyeloneuropathy
https://www.eib.org/en/press/all/2020-296-eib-provides-minoryx-with-up-to-eur25-million-to-support-development-of-breakthrough-therapies-in-orphan-neurodegenerative-diseases
https://en.prnasia.com/releases/global/minoryx-therapeutics-and-sperogenix-therapeutics-enter-into-an-exclusive-license-agreement-to-develop-and-commercialize-leriglitazone-in-mainland-china-hong-kong-and-macau-292572.shtml
https://www.ala.com/minoryx-therapeutics-doses-first-patient-with-leriglitazone-in-registration-enabling-cald-nexus-trial/
https://www.biospace.com/article/-minoryx-therapeutics-receives-approval-from-spanish-regulatory-agency-to-initiate-phase-2-study-in-friedreich-s-ataxia/